For men who undergo radical prostatectomy, a detectable PSA level that never fully clears has long been treated as an ominous independent risk factor — a signal that cancer remained active and resistant to surgery. New evidence from a large multicenter dataset challenges that interpretation and suggests the risk may be better explained by what PSMA-PET imaging reveals about underlying tumor distribution.
Drawing on a retrospective cohort of 1,188 prostate cancer patients across 11 centers in five countries, all of whom underwent PSMA-PET staging before salvage radiotherapy for biochemical recurrence, this analysis compared outcomes between those with PSA persistence versus PSA recurrence (a detectable rise after an initial undetectable nadir). PSMA-PET identified meaningfully different metastatic patterns between the two groups: patients with PSA persistence showed higher rates of local recurrence (43.5% vs. 30.0%) but lower rates of nodal failure (30.5% vs. 40.6%) compared to those with PSA recurrence. Critically, on univariate analysis, PSA recurrence was actually associated with superior 3-year biochemical progression-free survival (71.5% vs. 63.0%) and metastasis-free survival (83.0% vs. 78.0%), inverting the expected hierarchy.
This finding carries meaningful implications for how oncologists stratify post-surgical risk. The pre-PSMA-PET literature consistently flagged PSA persistence as a surrogate for occult systemic disease, but those studies were conducted without the ability to precisely localize residual or metastatic disease. PSMA-PET's markedly superior sensitivity for nodal and distant lesions now allows clinicians to interrogate whether PSA persistence reflects unresected local disease — potentially curable with salvage radiation — rather than inherently aggressive biology. The retrospective design, moderate follow-up median of 31 months, and lack of multivariate significance in some endpoints are notable limitations. Still, across a dataset of this size and geographic diversity, the consistency of the imaging-outcome pattern suggests that PSA persistence may need reclassification from independent prognostic marker to a staging artifact correctable by modern imaging — an incremental but clinically relevant reframing.